Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Duerr

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
AIDS Care|September 21, 2020
Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in KenyaJean de Dieu Tapsoba, Sahar Z Zangeneh, Eline Appelmans, et al.
BMC Cancer|January 28, 2025
ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIVDelia Pinto-Santini, Emilia M Jalil, Giovana Teixeira Fernandes, et al.
Journal of the National Cancer Institute|July 17, 2003
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive womenHoward D Strickler, Joel M Palefsky, Keerti V Shah, et al.
The Journal of Infectious Diseases|January 29, 2003
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative womenRaphael P Viscidi, Linda Ahdieh-Grant, Barbara Clayman, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
NPJ Vaccines|April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humansKelly E Seaton, Aaron Deal, Xue Han, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|November 18, 2008
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialSusan P Buchbinder, Devan V Mehrotra, Ann Duerr, et al.
AIDS Care|September 21, 2020
Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in KenyaJean de Dieu Tapsoba, Sahar Z Zangeneh, Eline Appelmans, et al.
BMC Cancer|January 28, 2025
ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIVDelia Pinto-Santini, Emilia M Jalil, Giovana Teixeira Fernandes, et al.
Journal of the National Cancer Institute|July 17, 2003
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive womenHoward D Strickler, Joel M Palefsky, Keerti V Shah, et al.
The Journal of Infectious Diseases|January 29, 2003
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative womenRaphael P Viscidi, Linda Ahdieh-Grant, Barbara Clayman, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
Plos One|September 3, 2015
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsYunda Huang, Dean Follmann, Martha Nason, et al.
NPJ Vaccines|April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humansKelly E Seaton, Aaron Deal, Xue Han, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Pageof 14